CytoNiche Raises ￥10 Million in Extended Series A Round

(VCBeat) Apr. 28, 2021 -- CytoNiche Biotechnology ("CytoNiche") today announced that it has extended the Series A financing by an additional ￥10 million, led by 3E Bioventures, with participation from the existing international industrial investor. According to CytoNiche, this round of financing will be used for the large-scale production of multi-type cell drugs, the development of the processing system of 3D micro cell carrier reagents and consumables and the new equipment covering the whole chain, and the expansion of the international market.

CytoNiche focuses on the research and development of 3D micro-tissue engineering technology. The core technology comes from the project conducted by Tsinghua University. Based on its original research technology, CytoNiche has launched a series of products and services, including customized, large-scale, automatic and intelligent stem cell culture and amplification process, 3D stem cell microtissue regeneration therapies and 3D cell high-throughput drug screening products.

CytoNiche now has a 1000m² R& D center and a 2000m² GMP production base. The company has obtained over 30 patents and published more than 30 articles in well-known international journals such as Nature Materials, PNAS, Nature Communication, Biomaterials, and have been widely reported at home and abroad.

3D FloTrix^® series products developed by CytoNiche are an original overall solution that can realize the large-scale culture and amplification of stem cells, as well as an innovation in pharmaceutical injection for stem cells. 3D FloTrix^® has obtained the certification of quality evaluation and safety evaluation by the National Institutes of Food and Drug Control, and the pharmaceutical excipient qualification record by FDADMF (DMF: 35481) in the United States, which is the only microcarrier product in the DMF record list published on the official website of FDA. The product has also received two pharmaceutical excipient qualifications from the National Medical Products Administration.

3E Bioventures is a specialized fund dedicated to investing in the world's leading life science and healthcare companies, focusing on innovative medicine and cross-innovation of medical devices and diagnostic technology. 3E Bioventures is a dual-currency fund with both RMB and US funds under management. It has invested and incubated more than 50 domestic and overseas medical enterprises and has offices in Beijing, Shanghai and Silicon Valley.